Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.
Ontology highlight
ABSTRACT: Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) results in a sustained virologic response (SVR) in most patients. While highly efficacious, ~3%-5% of patients do not achieve SVR despite having virus that appears susceptible. It is unclear whether host factors contribute to treatment failures, although innate and adaptive immunity may play a role. Previous studies showed that after DAA treatment, the composition of intrahepatic immune cells does not normalize relative to healthy volunteers, even in cases where SVR is achieved. We used paired pre- and post-treatment liver biopsies from 13 patients treated with sofosbuvir and ribavirin, 4 of whom relapsed, to analyse intracellular immune changes during DAA treatment and explore correlations with inf
SUBMITTER: Orr C
PROVIDER: S-EPMC6379130 | biostudies-literature | 2019 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA